Quick Answer
WEST PHARMACEUTICAL SERVICES INC reported Long Term Debt of $202.80 million for the year ending 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +0.1% in Long Term Debt from 2024 to 2025.
- This data is from WEST PHARMACEUTICAL SERVICES INC's annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $356.80 million | Q3 2010: $369.30 million | Q4 2010: $358.10 million | Q1 2011: $364.70 million | Q3 2011: $323.30 million | Q1 2012: $294.90 million | Q2 2012: $296.40 million | Q3 2012: $362.10 million | Q1 2013: $428.40 million | Q2 2013: $394.70 million | Q3 2013: $381.10 million | Q1 2014: $390.70 million | Q2 2014: $359.30 million | Q3 2014: $315.50 million | Q1 2015: $231.90 million | Q2 2015: $231.70 million | Q3 2015: $231.50 million | Q1 2016: $229.50 million | Q2 2016: $228.90 million | Q3 2016: $228.60 million | Q1 2017: $194.20 million | Q2 2017: $195.70 million | Q3 2017: $196.60 million | Q1 2018: $198.00 million | Q2 2018: $196.40 million | Q3 2018: $196.20 million | Q1 2019: $195.50 million | Q2 2019: $196.00 million | Q3 2019: $195.10 million | Q1 2020: $254.40 million | Q2 2020: $253.90 million | Q3 2020: $253.40 million | Q1 2021: $252.30 million | Q2 2021: $251.80 million | Q3 2021: $209.90 million | Q1 2022: $208.30 million | Q2 2022: $207.80 million | Q3 2022: $207.20 million | Q1 2023: $206.10 million | Q2 2023: $205.60 million | Q3 2023: $152.10 million | Q1 2024: $72.80 million | Q2 2024: $72.90 million | Q3 2024: $202.60 million | Q1 2025: $202.60 million | Q2 2025: $202.60 million | Q3 2025: $202.70 million.
- Over the full 17 years of available data (2009 to 2025), WEST PHARMACEUTICAL SERVICES INC's Long Term Debt has declined by 46.5%.
- Historical annual values: Fiscal year 2025: $202.80 million | Fiscal year 2024: $202.60 million | Fiscal year 2023: $72.80 million | Fiscal year 2022: $206.70 million | Fiscal year 2021: $208.80 million | Fiscal year 2020: $252.90 million | Fiscal year 2019: $255.00 million | Fiscal year 2018: $196.00 million | Fiscal year 2017: $197.00 million | Fiscal year 2016: $226.20 million | Fiscal year 2015: $228.90 million | Fiscal year 2014: $308.30 million | Fiscal year 2013: $371.30 million | Fiscal year 2012: $378.80 million | Fiscal year 2011: $299.30 million | Fiscal year 2010: $358.10 million | Fiscal year 2009: $379.10 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: